Do analysts recommend FTRE or STVN?

Fortrea presently has a consensus price target of $20.75, indicating a potential upside of 12.83%. Given Fortrea's higher possible upside, equities research analysts clearly believe Fortrea is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortrea 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media refer more to CAI or FTRE?

In the previous week, Caris Life Sciences had 1 more articles in the media than Fortrea. MarketBeat recorded 2 mentions for Caris Life Sciences and 1 mentions for Fortrea. Caris Life Sciences' average media sentiment score of 0.73 beat Fortrea's score of 0.00 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SHC or FTRE more profitable?

Sotera Health has a net margin of 13.44% compared to Fortrea's net margin of -3.18%. Sotera Health's return on equity of 40.12% beat Fortrea's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 13.44% 40.12% 7.55% Fortrea -3.18% 10.72% 2.17%

Does the media favor SHC or FTRE?

In the previous week, Sotera Health had 6 more articles in the media than Fortrea. MarketBeat recorded 7 mentions for Sotera Health and 1 mentions for Fortrea. Sotera Health's average media sentiment score of 0.36 beat Fortrea's score of 0.00 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ADPT or FTRE?

In the previous week, Adaptive Biotechnologies had 16 more articles in the media than Fortrea. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 1 mentions for Fortrea. Adaptive Biotechnologies' average media sentiment score of 0.70 beat Fortrea's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALMR or FTRE?

In the previous week, Alamar Biosciences had 2 more articles in the media than Fortrea. MarketBeat recorded 3 mentions for Alamar Biosciences and 1 mentions for Fortrea. Alamar Biosciences' average media sentiment score of 0.46 beat Fortrea's score of 0.00 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fortrea (FTRE) Competitors

$18.39 +0.20 (+1.10%)

As of 08/21/2026 04:00 PM Eastern

Compare

FTRE vs. STVN, CAI, SHC, ADPT, and ALMR

Should you buy Fortrea stock or one of its competitors? Fortrea's main competitors and comparable companies include Stevanato Group (STVN), Caris Life Sciences (CAI), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), and Alamar Biosciences (ALMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Fortrea compare to Stevanato Group?

Fortrea (NASDAQ:FTRE) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Fortrea has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Fortrea presently has a consensus price target of $20.75, indicating a potential upside of 12.83%. Given Fortrea's higher possible upside, equities research analysts clearly believe Fortrea is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Stevanato Group has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.64	-$986.20M	-$0.91	N/A
Stevanato Group	€1.34B	5.10	€158.21M	€0.56	40.36

Stevanato Group has a net margin of 10.99% compared to Fortrea's net margin of -3.18%. Fortrea's return on equity of 10.72% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Stevanato Group	10.99%	10.43%	6.16%

In the previous week, Fortrea had 1 more articles in the media than Stevanato Group. MarketBeat recorded 1 mentions for Fortrea and 0 mentions for Stevanato Group. Fortrea's average media sentiment score of 0.00 equaled Stevanato Group'saverage media sentiment score.

Company	Overall Sentiment
Fortrea	Neutral
Stevanato Group	Neutral

Summary

Stevanato Group beats Fortrea on 8 of the 14 factors compared between the two stocks.

How does Fortrea compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Caris Life Sciences currently has a consensus price target of $26.33, indicating a potential upside of 0.24%. Fortrea has a consensus price target of $20.75, indicating a potential upside of 12.83%. Given Fortrea's higher possible upside, analysts plainly believe Fortrea is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Caris Life Sciences has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$348.89M	21.28	-$68.09M	$0.36	72.97
Fortrea	$2.72B	0.64	-$986.20M	-$0.91	N/A

Caris Life Sciences has a net margin of 10.62% compared to Fortrea's net margin of -3.18%. Caris Life Sciences' return on equity of 18.77% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Caris Life Sciences had 1 more articles in the media than Fortrea. MarketBeat recorded 2 mentions for Caris Life Sciences and 1 mentions for Fortrea. Caris Life Sciences' average media sentiment score of 0.73 beat Fortrea's score of 0.00 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Caris Life Sciences has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

Summary

Caris Life Sciences beats Fortrea on 11 of the 14 factors compared between the two stocks.

How does Fortrea compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

91.0% of Sotera Health shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 0.7% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sotera Health has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.80	$77.94M	$0.57	34.33
Fortrea	$2.72B	0.64	-$986.20M	-$0.91	N/A

Sotera Health has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Sotera Health currently has a consensus target price of $21.50, suggesting a potential upside of 9.86%. Fortrea has a consensus target price of $20.75, suggesting a potential upside of 12.83%. Given Fortrea's higher possible upside, analysts clearly believe Fortrea is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sotera Health has a net margin of 13.44% compared to Fortrea's net margin of -3.18%. Sotera Health's return on equity of 40.12% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Sotera Health had 6 more articles in the media than Fortrea. MarketBeat recorded 7 mentions for Sotera Health and 1 mentions for Fortrea. Sotera Health's average media sentiment score of 0.36 beat Fortrea's score of 0.00 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sotera Health beats Fortrea on 13 of the 16 factors compared between the two stocks.

How does Fortrea compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Adaptive Biotechnologies had 16 more articles in the media than Fortrea. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 1 mentions for Fortrea. Adaptive Biotechnologies' average media sentiment score of 0.70 beat Fortrea's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 0.7% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Fortrea has a net margin of -3.18% compared to Adaptive Biotechnologies' net margin of -20.73%. Fortrea's return on equity of 10.72% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Fortrea	-3.18%	10.72%	2.17%

Adaptive Biotechnologies has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

Adaptive Biotechnologies presently has a consensus price target of $24.42, indicating a potential downside of 6.05%. Fortrea has a consensus price target of $20.75, indicating a potential upside of 12.83%. Given Fortrea's higher probable upside, analysts plainly believe Fortrea is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Adaptive Biotechnologies has higher earnings, but lower revenue than Fortrea. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	14.98	-$59.50M	-$0.41	N/A
Fortrea	$2.72B	0.64	-$986.20M	-$0.91	N/A

Summary

Adaptive Biotechnologies beats Fortrea on 9 of the 15 factors compared between the two stocks.

How does Fortrea compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Alamar Biosciences currently has a consensus price target of $31.80, suggesting a potential downside of 7.13%. Fortrea has a consensus price target of $20.75, suggesting a potential upside of 12.83%. Given Fortrea's higher possible upside, analysts clearly believe Fortrea is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Alamar Biosciences had 2 more articles in the media than Fortrea. MarketBeat recorded 3 mentions for Alamar Biosciences and 1 mentions for Fortrea. Alamar Biosciences' average media sentiment score of 0.46 beat Fortrea's score of 0.00 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has a net margin of 0.00% compared to Fortrea's net margin of -3.18%. Fortrea's return on equity of 10.72% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Fortrea	-3.18%	10.72%	2.17%

Alamar Biosciences has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	32.02	-$29.82M	-$1.96	N/A
Fortrea	$2.72B	0.64	-$986.20M	-$0.91	N/A

Summary

Alamar Biosciences beats Fortrea on 7 of the 13 factors compared between the two stocks.

Get Fortrea News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTRE vs. The Competition

Export

Metric	Fortrea	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.75B	$10.24B	$7.37B	$12.85B
Dividend Yield	N/A	1.46%	2.54%	11.08%
P/E Ratio	-20.21	61.54	272.88	24.24
Price / Sales	0.64	110.30	618.96	99.76
Price / Cash	1.85	27.04	78.62	53.99
Price / Book	3.34	37.34	13.05	6.20
Net Income	-$986.20M	$56.67B	$3.47B	$348.59M
7 Day Performance	5.63%	5.24%	2.09%	0.08%
1 Month Performance	-5.69%	9.02%	6.64%	3.88%
1 Year Performance	120.50%	24.45%	25.02%	16.98%

Fortrea Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTRE Fortrea	2.6416 of 5 stars	$18.39 +1.1%	$20.75 +12.8%	+120.5%	$1.75B	$2.72B	N/A	14,300
STVN Stevanato Group	3.5311 of 5 stars	€21.47 +1.0%	N/A	+0.4%	€6.50B	€1.34B	38.34	6,010
CAI Caris Life Sciences	1.8232 of 5 stars	$21.63 -0.8%	$26.33 +21.7%	N/A	$6.16B	$812.03M	60.08	1,846	Analyst Upgrade
SHC Sotera Health	3.6182 of 5 stars	$18.80 -0.5%	$21.50 +14.4%	+19.1%	$5.39B	$1.16B	32.98	3,000	Insider Trade High Trading Volume
ADPT Adaptive Biotechnologies	1.5113 of 5 stars	$24.77 +0.1%	$24.42 -1.4%	+99.9%	$3.95B	$308.08M	N/A	790	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTRE) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortrea (FTRE) Competitors

FTRE vs. STVN, CAI, SHC, ADPT, and ALMR

How does Fortrea compare to Stevanato Group?

Summary

How does Fortrea compare to Caris Life Sciences?

Summary

How does Fortrea compare to Sotera Health?

Summary

How does Fortrea compare to Adaptive Biotechnologies?

Summary

How does Fortrea compare to Alamar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE vs. The Competition

Fortrea Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortrea (FTRE) Competitors

FTRE vs. STVN, CAI, SHC, ADPT, and ALMR

How does Fortrea compare to Stevanato Group?

Which has more volatility and risk, FTRE or STVN?

Do analysts recommend FTRE or STVN?

Which has stronger valuation and earnings, FTRE or STVN?

Is FTRE or STVN more profitable?

Does the media prefer FTRE or STVN?

Summary

How does Fortrea compare to Caris Life Sciences?

Do analysts prefer CAI or FTRE?

Which has stronger valuation and earnings, CAI or FTRE?

Is CAI or FTRE more profitable?

Does the media refer more to CAI or FTRE?

Which has more risk and volatility, CAI or FTRE?

Summary

How does Fortrea compare to Sotera Health?

Do institutionals & insiders hold more shares of SHC or FTRE?

Which has higher valuation & earnings, SHC or FTRE?

Which has more volatility and risk, SHC or FTRE?

Do analysts prefer SHC or FTRE?

Is SHC or FTRE more profitable?

Does the media favor SHC or FTRE?

Summary

How does Fortrea compare to Adaptive Biotechnologies?

Does the media prefer ADPT or FTRE?

Do insiders and institutionals believe in ADPT or FTRE?

Is ADPT or FTRE more profitable?

Which has more volatility & risk, ADPT or FTRE?

Do analysts rate ADPT or FTRE?

Which has better earnings & valuation, ADPT or FTRE?

Summary

How does Fortrea compare to Alamar Biosciences?

Do analysts recommend ALMR or FTRE?

Does the media refer more to ALMR or FTRE?

Is ALMR or FTRE more profitable?

Which has preferable valuation & earnings, ALMR or FTRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE vs. The Competition

Fortrea Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools